Guardant Health, Inc. · NASDAQ:GH
Guardant Health — Technical Presentation (December 2022)
10 slides from Guardant Health's technical presentation, Dec 15, 2022
Slide 1: ECLIPSE Readout
ECLIPSE Readout December 15, 2022
Slide 2: Safe Harbor
Safe Harbor Certain statements in this presentation and the accompanying oral commentary are forward-looking many of which are beyond the Company's control. These and other important factors may cause statements within the meaning of federal securities laws. These statements relate to future events
Slide 3: Positive ECLIPSE Study Results
Positive ECLIPSE Study Results Paves the way for first potential FDA-approved and Medicare-reimbursed blood test for CRC screening 83% 90% 90% 13% CRC Sensitivity Specificity Specificity AA Detection (Overall) (Advanced Neoplasia) (Normal Colonoscopy) 3 CRC: Colorectal Carcinoma; AA: advanced Adenom
Slide 4: Study Participants From Diverse Backgrounds and Settings
Study Participants From Diverse Backgrounds and Settings SITE ENROLLMENT >200 sites • Across 34 states • Every geographic region in the continental U.S. Conducted in both rural and urban locations • Community hospitals • GI clinics • Private practices • Academic medical centers 34 states across ever
Slide 5: ECLIPSE Study: Analyzed Cohort Demographic
ECLIPSE Study: Analyzed Cohort Demographic Age Group Race 2.3% 0.2% 0.2% 6.7% 45-59 45% 60-69 32% 13.2% 70+ 23% Gender Female 54% Male 47% Ethnicity 77.4% Non-Hispanic 84% White Black or African American Hispanic Asian Other 15% Native Hawaiian or Other Pacific Islander American Indian or Alaskan Na
Slide 6: 2022 CRC Screening Compliance in the United States
2022 CRC Screening Compliance in the Unites States 137M Individuals Ages 45 – 851 17M High Risk Individuals 120M Avg Risk Individuals (88%)2 (12%)2 49M Unscreened Individuals3 (41%) 71M Screened Individuals (59%)3 16M Potential Tests Annually FIT/FOBT Cologuard Colonoscopy 6.7M Tests Annually3 2.8M
Slide 7: Blood-based CRC Screening Demonstrates Improved Adherence to Screening in a Real-world Setting
Blood-based CRC Screening Demonstrates Improved Adherence to Screening in a Real-world Setting Industry benchmark >8k >90% ~65% Orders placed by end of Sep Adherence rate for first 8k patients1 Adherence rate2 Patient survey demonstrates preference for blood test over stool and colonoscopy methods F
Slide 8: Long-term Adoption of Blood-Based CRC Screening
Long-term Adoption of Blood-Based CRC Screening, Boosted by Patient Preference and Multi-Cancer Screening FDA Approval, CMS reimbursement, guidelines inclusion Screening Market Size Blood-Based CRC 10M+ Patient Preference Tests1 Multi-cancer boosters Profitable $5B+ revenue opportunity 3 – 4M Tests1
Slide 9: Unlocking a $20B opportunity for CRC screening in 2022 & beyond
Unlocking a $20B opportunity for CRC screening in 2022 & beyond Positive ECLIPSE readout Complete PMA submission to FDA expected in 1Q’23 ECLIPSE Readout 4Q’ 22 Launched Submit for FDA Medicare Coverage Guidelines Shield LDT FDA Approval Approval & ADLT Status May 2022 1Q’ 23 Early 2024 2026 Drives
Slide 10: Guardant
(@) GUARDANT
Guardant Health — Technical Presentation (December 2022) on 6ix